tiprankstipranks
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
US Market

Nurix Therapeutics Stock Analysis & Ratings

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NRIX FAQ

What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $7.52 and its highest was $37.42 in the past 12 months.
    What is Nurix Therapeutics’s market cap?
    Currently, no data Available
    What is Nurix Therapeutics’s price target?
    The average price target for Nurix Therapeutics is $37.89. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $54.00 ,the lowest forecast is $25.00. The average price target represents 96.73% Increase from the current price of $19.26.
      What do analysts say about Nurix Therapeutics?
      Nurix Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
        When is Nurix Therapeutics’s upcoming earnings report date?
        Nurix Therapeutics’s upcoming earnings report date is Oct 19, 2022 which is in 71 days.
          How were Nurix Therapeutics’s earnings last quarter?
          Nurix Therapeutics released its earnings results on Jul 07, 2022. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.971 by -$0.039.
            Is Nurix Therapeutics overvalued?
            According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Nurix Therapeutics pay dividends?
              Nurix Therapeutics does not currently pay dividends.
              What is Nurix Therapeutics’s EPS estimate?
              Nurix Therapeutics’s EPS estimate is -$0.95.
                How many shares outstanding does Nurix Therapeutics have?
                Nurix Therapeutics has 47,041,874 shares outstanding.
                  What happened to Nurix Therapeutics’s price movement after its last earnings report?
                  Nurix Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.971. Following the earnings report the stock price went up 14.48%.
                    Which hedge fund is a major shareholder of Nurix Therapeutics?
                    Among the largest hedge funds holding Nurix Therapeutics’s share is ARK Investment Management LLC. It holds Nurix Therapeutics’s shares valued at 5M.

                      ---

                      Nurix Therapeutics Stock Analysis

                      The Nurix Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Nurix Therapeutics

                      Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AbbVie
                      Amgen
                      Gilead Sciences
                      Moderna
                      Vertex Pharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis